Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer

NCT01918306 is registered in ClinicalTrials.gov with Vanderbilt-Ingram Cancer Center as lead sponsor.

NCT NCT01918306
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01918306 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer
Lead sponsor
Vanderbilt-Ingram Cancer Center
Phase
Phase 1/2
Overall status
Terminated
Start date
September 30, 2013
Completion date
April 30, 2015
Enrollment
11 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

estrogen receptor negative breast cancer, human epidermal growth factor 2 negative carcinoma of breast, recurrent breast cancer, stage iv breast cancer, triple negative breast cancer, triple-negative breast cancer